Interfering with CXCR4 expression inhibits proliferation, adhesion and migration of breast cancer MDA‑MB‑231 cells

Guo,Shanyu; Xiao,Dan; Liu,Huihui; Zheng,Xiao; Liu,Lei; Liu,Shougui

doi:10.3892/ol.2014.2323

Interfering with CXCR4 expression inhibits proliferation, adhesion and migration of breast cancer MDA‑MB‑231 cells

Authors:
- Shanyu Guo
- Dan Xiao
- Huihui Liu
- Xiao Zheng
- Lei Liu
- Shougui Liu
View Affiliations

Affiliations: Department of General Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China
Published online on: July 7, 2014 https://doi.org/10.3892/ol.2014.2323
Pages: 1557-1562

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate the effect and mechanism of the CXC chemokine receptor 4 (CXCR4) in the proliferation and migration of breast cancer, a short‑hairpin RNA (shRNA) eukaryotic expression vector targeting CXCR4 was constructed, and the impact of such on the proliferation, adhesion and migration of human breast cancer MDA‑MB‑231 cells was observed. The fragments of CXCR4‑shRNA were synthesized and cloned into a pGCsi‑U6‑Neo‑green fluorescent protein vector. The recombinant plasmids were transfected into 293T cells and the most efficacious interfering vector was selected. MDA‑MB‑231 cells were transfected by liposome assay. The effects of silencing CXCR4 expression by shRNA on the growth, adhesion and migration of MDA‑MB‑231 cells were determined by Cell Counting Kit‑8, cell‑matrix adhesion and wound‑healing assays. The shRNA eukaryotic expression vectors targeting CXCR4 (CXCR4‑shRNA) were successfully constructed and transfected into 293T cells. Quantitative polymerase chain reaction and western blot analysis revealed that the maximum inhibitory rate of CXCR4 expression was 81.3%. CXCR4‑shRNA transfection significantly inhibited the proliferation of MDA‑MB‑231 cells (P<0.05), as well as the adhesion between MDA‑MB‑231 cells and the extracellular matrix (P<0.05). Furthermore, wound‑healing assays demonstrated that the migration distance of MDA‑MB‑231 cells in the CXCR4‑shRNA transfection group was significantly smaller than that in the control plasmid and blank control groups (P<0.01). The CXCR4‑shRNA interfering vector specifically inhibited CXCR4 expression, as well as the proliferation, adhesion and migration of MDA‑MB‑231 cells.

View Figures

View References

1	Sellers TA: Genetic factors in the pathogenesis of breast cancer: their role and relative importance. J Nutr. 27(5 Suppl): 929S–932S. 1997.
2	Psaila B and Lyden D: The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 9:285–293. 2009.
3	Yarden Y: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001.
4	Ghosh R, Narasanna A, Wang SE, et al: Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 71:1871–1882. 2011.
5	Kulbe H, Levinson NR, Balkwill F and Wilson JL: The chemokine network in cancer - much more than directing cell movement. Int J Dev Biol. 48:489–496. 2004.
6	Kuhlmann CR, Schaefer CA, Reinhold L, Tillmanns H and Erdogan A: Signalling mechanisms of SDF-induced endothelial cell proliferation and migration. Biochem Biophys Res Commun. 335:1107–1114. 2005.
7	Wang J, Wang J, Sun Y, et al: Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal. 17:1578–1592. 2005.
8	Chu H, Zhou H, Liu Y, et al: Functional expression of CXC chemokine recepter-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability. Int J Biochem Cell Biol. 39:197–205. 2007.
9	Tang J, Zhang L, She X, et al: Inhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation, mobility, and metastasis in vitro and in vivo. Cancer Invest. 30:380–389. 2012.
10	David NB, Sapède D, Saint-Etienne L, et al: Molecular basis of cell migration in the fish lateral line: role of the chemokine receptor CXCR4 and of its ligand, SDF1. Proc Natl Acad Sci USA. 99:16297–16302. 2002.
11	Babcock GJ, Farzan M and Sodroski J: Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J Biol Chem. 278:3378–3385. 2003.
12	Sun YX, Wang J, Shelburne CE, et al: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 89:462–473. 2003.
13	Phillips RJ, Burdick MD, Lutz M, et al: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 167:1676–1686. 2003.
14	Koshiba T, Hosotani R, Miyamoto Y, et al: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 6:3530–3535. 2000.
15	Raman D, Baugher PJ, Thu YM and Richmond A: Role of chemokines in tumor growth. Cancer Lett. 256:137–165. 2007.
16	Sun YX, Fang M, Wang J, et al: Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate. 67:61–73. 2007.
17	Sutton A, Friand V, Brulé-Donneger S, et al: Stromal cell-derived factor-1/chemokine (CXC motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res. 5:21–33. 2007.
18	Smith MC, Luker KE, Garbow JR, et al: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 64:8604–8612. 2004.
19	Hannon GJ: RNA interference. Nature. 418:244–251. 2002.
20	Elbashir SM, Lendeckel W and Tuschl T: RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev. 15:188–200. 2001.
21	Aravin AA, Klenov MS, Vagin VV, Rozovskiĭ IaM and Gvozdev VA: Role of double-stranded RNA in eukaryotic gene silencing. Mol Biol (Mosk). 36:240–251. 2002.(In Russian).
22	Sanguino A, Lopez-Berestein G and Sood AK: Strategies for in vivo siRNA delivery in cancer. Mini Rev Med Chem. 8:248–255. 2008.
23	Lapteva N, Yang AG, Sanders DE, Strube RW and Chen SY: CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther. 12:84–89. 2005.
24	Ueda Y, Neel NF, Schutyser E, Raman D and Richmond A: Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. Cancer Res. 66:5665–5675. 2006.
25	Yoon Y, Liang Z, Zhang X, et al: CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res. 67:7518–7524. 2007.
26	Zeelenberg IS, Ruuls-Van Stalle L and Roos E: The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 63:3833–3839. 2003.
27	Huang EH, Singh B, Cristofanilli M, et al: A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 155:231–236. 2009.
28	Richert MM, Vaidya KS, Mills CN, et al: Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep. 21:761–767. 2009.